Treatments and vaccines for COVID-19: research and development
The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 treatments and vaccines to enable promising medicines to reach patients in the European Union (EU) as soon as possible.
EMA is providing guidance to assist developers of potential COVID-19 medicines to prepare for eventual applications for marketing authorisation.
This includes scientific advice and as informal consultation with the COVID-19 EMA pandemic Task Force (COVID-ETF).
The outcome of any consultation or advice from EMA is not binding on developers.
This information should not be read as an endorsement of any medicine.
Information on ongoing COVID-19 clinical trials in the European Economic Area (EEA) is available in the EU Clinical Trials Register (EU CTR):
Users can find information on:
- phase II to phase IV adult clinical trials where the investigator sites are in the EEA;
- any clinical trials in children with investigator sites in the EU and any trials that form part of a paediatric investigation plan, including those where the investigator sites are outside the EU.
Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.
For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see Clinical trials in human medicines.
Medicine regulatory authorities worldwide are also cooperating under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA) to expedite and streamline the development of COVID-19 vaccines and treatments.
For more information, see ICMRA: Cooperation to support the development of COVID-19 vaccines and treatments.